Phase 3
-
A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
Phase 3 · randomised · 165 people · 2 sites in China · Recruiting now
-
Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
Phase 3 · randomised · 210 people · 1 site in China · Recruiting now
-
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
Phase 3 · randomised · 308 people · 1 site in South Korea · Recruiting now
-
Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
Phase 3 · randomised · 556 people · 1 site in China · Recruiting now
-
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Phase 3 · randomised · 156 people · 1 site in China · Recruiting now
-
Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance
Phase 3 · randomised · 140 people · 5 sites in Switzerland · Recruiting now
-
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer
Phase 3 · randomised · 582 people · 1 site in China · Recruiting now
-
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Phase 3 · randomised · 386 people · 1 site in China · Recruiting now